Literature DB >> 16389029

Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses.

Jacob H Rand1, Alan A Arslan, Xiao-Xuan Wu, Rosemary Wein, Jeanine Mulholland, Manish Shah, Waander L van Heerde, Chris P Reutelingsperger, Charles J Lockwood, Edward Kuczynski.   

Abstract

OBJECTIVE: We investigated whether levels of annexin A5, evidence for resistance to annexin A5 activity, and levels anti-annexin A5 antibodies might be altered in women with a history of recurrent spontaneous pregnancy losses. STUDY
DESIGN: These annexin A5 parameters were assayed in 70 nonpregnant women with a history of > or = 3 recurrent spontaneous pregnancy losses (cases) and 50 women without adverse pregnancy history (control subjects).
RESULTS: Cases had significantly lower plasma annexin A5 levels than control subjects (median, 4.7 ng/mL [range, 0.3-40.4 ng/mL] vs 6.7 ng/mL [range, 0.7-56.0]; P = .01), significantly reduced anticoagulant ratios (188% [range, 119%-279%] vs 238% [range, 159%-286%]; P < .0001), and reduced binding of annexin A5 to phospholipid (6.3 ng/aliquot phospholipid [range, 1.5-16.4 ng/aliquot phospholipid] vs 9.7 ng/aliquot phospholipid (range, 3.5-17.0 ng/aliquot phospholipid]; P = .0002). There were no significant differences in anti-annexin A5 antibody levels.
CONCLUSION: Reduction of annexin A5 and interference with its anticoagulant and binding activities are associated significantly with a history of recurrent spontaneous pregnancy losses. These data support the concept of a significant role for annexin A5 in the maintenance of pregnancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16389029     DOI: 10.1016/j.ajog.2005.05.034

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

1.  Evaluation of plasma annexin V levels in children and young adults with solid tumors.

Authors:  Mark A Applebaum; Elise Sambrano; Sharon Lee; Robert Goldsby; Katherine K Matthay; Steven G DuBois
Journal:  Int J Biol Markers       Date:  2012-07-19       Impact factor: 2.659

2.  Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Authors:  D M Wahezi; N T Ilowite; X X Wu; L Pelkmans; B Laat; L E Schanberg; J H Rand
Journal:  Lupus       Date:  2013-05-20       Impact factor: 2.911

3.  Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome.

Authors:  Beverley J Hunt; Xiao-Xuan Wu; Bas de Laat; Alan A Arslan; Sara Stuart-Smith; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-15       Impact factor: 8.661

4.  Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.

Authors:  Xiao-Xuan Wu; Seth Guller; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-24       Impact factor: 8.661

5.  The haplotype M2 of the ANXA5 gene is not associated with antitrophoblast antibodies.

Authors:  Nina Rogenhofer; Laura Engels; Nadja Bogdanova; Frank Tüttelmann; Arseni Markoff; Christian J Thaler
Journal:  J Assist Reprod Genet       Date:  2013-03-27       Impact factor: 3.412

6.  Measurement of the binding parameters of annexin derivative-erythrocyte membrane interactions.

Authors:  Tzu-Chen Yen; Shiaw-Pyng Wey; Chang-Hui Liao; Chi-Hsiao Yeh; Duan-Wen Shen; Samuel Achilefu; Tze-Chein Wun
Journal:  Anal Biochem       Date:  2010-07-01       Impact factor: 3.365

7.  Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Marija Sarić; Ljudmila Stojanovich; Duško Mirković; Violeta Dopsaj; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2018-06-12       Impact factor: 2.980

Review 8.  Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.

Authors:  Claire de Moreuil; Zarrin Alavi; Elisabeth Pasquier
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

Review 9.  Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy.

Authors:  Anthony S Quinn; Xiao-Xuan Wu; Jacob H Rand; Douglas J Taatjes
Journal:  Micron       Date:  2012-03-23       Impact factor: 2.251

10.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.